In 2009, a small hallmark RCT on GM-CSF therapy for patients with sepsis used mHLA-DR values below 8,000 molecules/cell (for 2 subsequent days) as inclusion criteria and found GM-CSF to be able to reconstitute immune function as well as to decrease duration of mechanical ventilation (25). This evidence concerns the gene CSF2 and Sepsis.